Slide 1: Cover letter to stock exchanges
10th May, 2022 (1) BSE Ltd. (2) National Stock Exchange of India Ltd. Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor, Dalal Street Plot no. C/1, G Block, Mumbai 400 001 Bandra (East), Mumbai ‐ 400 051 Scrip Code: 500087 Scrip Code: 500087 (3) SOCIETE DE LA
Slide 2: Investor Presentation Q4FY22
CLICK TO EDIT MASTER TITLE STYLE Investor Presentation Q4FY22 10-5-2022
Slide 3: Disclaimer
DISCLAIMER CLICK TO EDIT MASTER TITLE STYLE Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact o
Slide 4: In FY22, we delivered strong performance across our key markets
In FY22, we delivered strong performance across our key CLICKupward markets; TO EDIT operating MASTER TITLE STYLE profitability trajectory sustained Revenue (YoY Growth in INR terms) EBITDA Margin R&D Spends2 Overall Cipla Overall 14% Overall 21% 21% Ex-covid 12% Adj. margin1 ~22% (YoY Growth) (YoY
Slide 5: Strong traction in One-India and US business drive Q4FY22 performance
Strong traction in One-India and US business drive Q4FY22 CLICK TO EDIT performance; CoreMASTER TITLE STYLE profitability maintains strong trajectory Overall Revenue Overall EBITDA EBITDA Margin Adj1 EBITDA Margin R&D spends2 14% Sustained traction across (Q4 YoY Growth in INR Terms) branded & gener
Slide 6: Continued focus on maintaining a strong balance sheet
Continued focus on maintaining a strong balance sheet CLICK health andTO EDIT MASTER robust TITLE free cash STYLE flow generation Total Debt (INR Cr) Cash Balances1 Net Cash2 / Equity (INR Cr) Pre-paid 1,756 InvaGen 4,965 0.20 acquisition debt; nil 3,756 outstanding 824 0.11 Mar'21 Mar'22 Mar'21 Mar
Slide 7: Financial Performance – Q4FY22
Financial Performance – Q4FY22 CLICK TO EDIT MASTER TITLE STYLE Revenues INR 5,260 Cr 14% YoY EBITDA2 INR 763 Cr │ 14.5% 4% YoY Q4 FY22 (Consolidated) Revenue1 Break-up Actuals API, 3% vs Q4 FY 21 Others, 1% (INR Cr) International Total Revenue from Markets, 5,260 14% 14% Operations EBITDA2 763 -4%
Slide 8: Financial Performance – FY22
Financial Performance – FY22 CLICK TO EDIT MASTER TITLE STYLE Revenues INR 21,763 Cr 14% YoY EBITDA INR 4,578 Cr │ 21% 6% YoY FY22 (Consolidated) Revenue1 Break-up Actuals API, 3% vs FY 21 Others, 1% (INR Cr) International Total Revenue from Markets, 21,763 14% Operations 13% EBITDA2 4,578 6% India,
Slide 9: One India (Rx + Gx + CHL) execution and portfolio synergies
One India (Rx + Gx+ CHL1): Over the last 2 years we have driven strong CLICKacross execution TO EDIT MASTERand portfolio TITLE STYLE distribution synergies helping us drive growth across the three businesses Prescription Trade generics Consumer health Overall One-India One-India Ex-Covid 9,828 INR C
Slide 10: Core branded prescription portfolio therapy mix across chronic and acute
Cipla’s core branded prescription portfolio therapy mix reflect strong fundamentals CLICK TOacross chronic and EDIT MASTER TITLEacute STYLEsegments; big brands growing bigger in size and brand equity High-quality branded Core Acute portfolio 41% 5% Core Chronic portfolio 59% 750bps+ 13% franchise ac
Slide 11: Global consumer wellness franchise
Global consumer wellness franchise committed to provide CLICKand a holistic TO EDIT MASTER TITLE customized STYLEsolutions wellness ~8% contribution to overall revenues in FY22; Improving consumer health outcomes Anchor consumer brands in India1 Anchor consumer brands in South Africa 8% #1 #1 17% Pa
Slide 12: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global CLICK TO EDIT MASTER TITLE STYLE Access $ Mn South Africa2 Q4 Y-o-Y ❖ Market beating growth continues in South Africa (SA) private business; Brands launched in 33 38 SA Private 5 tender business muted in-line with Q4FY22 23 18 expectations mar
Slide 13: North America: Continued traction in core formulation business
North America: Continued traction in core formulation CLICKdriven business TO EDIT byMASTER TITLE franchise respiratory STYLE and peptide assets Key Business Highlights North America ❖ Revenue at multi-quarter high of $160 Mn ❖ Robust momentum in core formulation business; strong traction in $ Mn re
Slide 14: ANDA & NDA Portfolio & Pipeline (As on 31st March 2022)
ANDA & NDA1 Portfolio & Pipeline (As on 31st March 2022) CLICK TO EDIT MASTER TITLE STYLE Total ANDAs 169 19 69 257 & NDAs 24 61 8 5 16 7 76 3 41 1 9 6 Approved Tentatively Under Approval ANDAs/NDAs Approved ANDAs ANDAs/NDAs 2 Cipla Ltd PEFPAR Invagen Partnered ANDAs 1 Does not include Vet product A
Slide 15: International Markets and API
International Markets and API CLICK TO EDIT MASTER TITLE STYLE International Markets API FY22 Y-o-Y: 1% FY22 Y-o-Y: -5% $ Mn Q4 Y-o-Y $ Mn Q4 Y-o-Y 93 4% 97 31 -41% 18 Q4FY21 Q4FY22 Q4FY21 Q4FY22 Key Business Highlights Key Business Highlights ❖ Scale supported by strong DTM1 growth across geographi
Slide 16: Progress on strategic priorities for FY25
In FY22, we delivered strong progress on our strategic CLICK TO EDIT MASTER TITLE STYLE priorities for FY25 FY25 targets YTD FY22 progress Launch & scale-up in Expanding lung leadership globally and maximising value opportunity in Incremental opportunity to respiratory assets Albuterol & US complex
Slide 17: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com Ankit Bhembre Investor.Relations@cipla.com For more information please visit www.cipla.com